Adcentrx Therapeutics, a San Diego-headquartered biopharmaceutical firm engaged in developing Antibody-Drug Conjugate (ADC) therapeutics for cancer, has closed a $38-million extended Series A financing round led by Fidelity-backed global venture capital firm Eight Roads Ventures.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
